Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filters aim to reverse organ failure in septic shock

NCT ID NCT07661303

Disease control Sponsor: Moscow Multidisciplinary Clinical Center "Kommunarka" Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether special blood purification devices can help people with septic shock, a life-threatening condition where infection causes organ failure. The trial includes adults aged 18 to 80 with severe septic shock. Depending on their level of endotoxins, patients receive either a device that targets bacterial toxins or one that removes general inflammatory substances. The goal is to see if these treatments improve organ function within 72 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood purification devices (Efferon LPS, Toramyxin PMX 20R, Jafron HA 330, CytoSorb)
What this could lead to
If effective, these blood purification methods could offer a new way to reduce organ failure and improve survival in septic shock.
What could go wrong
This is a small pilot study, so results may not be definitive. The devices are compared against each other, not a placebo, and septic shock is complex with many variables.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Septic shock according to SEPSIS-3 criteria * Age: 18-80 years * SOFA ≥9 points * Diagnosis of septic shock established \<12 hours ago * Invasive hemodynamic monitoring * Norepinephrine dose \>0.2 mcg/kg/min Exclusion Criteria: * Absolute neutrophil count less than 500 cells/μL * Pregnancy * End-stage heart failure (NYHA stage IV) * Pulmonary embolism with obstructive shock * Ongoing bleeding * Atonic coma * More than 30 points on the MELD scale, class C on the Child-Pugh scale * HIV infection * Burns over 10% of the body surface area * Patients with oncohematological diseases * Patients with a recognized palliative status or the definition of "metastatic cancer" * RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure * Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Endotoxemia multiple organ dysfunction syndrome toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bakulev Scientific Center of Cardiovascular Surgery

    Moscow, Russia

  • City Clinical Hospital No 52, Moscow, Russia

    Moscow, Russia

  • City clinical hospital named after S. S. Yudin, Moscow City Health

    Moscow, Russia

  • Moscow Multi-disciplinary Clinical Center "Kommunarka"

    Moscow, Russia

  • National Medical Research Centre for Oncology Rostov-on-Don

    Rostov-on-Don, Russia

  • Petrovsky National Research Centre of Surgery

    Moscow, Russia

  • Sklifosovsky Institute of Emergency Care

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.